A recent study suggests that people who stop using popular GLP-1 drugs like semaglutide or tirzepatide can put back on shed pounds far faster than those who end conventional lifestyle regimens.
Findings released in a major health publication points out that while obese individuals can lose a large proportion of their body weight while undergoing treatment, the mass is regained at an average rate of nearly a kilo each month after stopping.
"Users purchasing these drugs need to be informed of the danger of fast weight regain when the treatment is stopped," warns expert Dr. Susan Jebb.
This pace of recovery means a reversion to pre-treatment mass in about 18 months.
Comparing Therapies
The analysis, which examined 37 of trials involving thousands of patients, compared the results of these new drugs with older methods.
The team emphasize that individuals who lose weight through lifestyle changes alone generally experience a slower weight regain—approximately 100 grams monthly—post-intervention.
Understanding the Rapid Rebound
Nutrition scientists propose the mechanism of the injections explains the heightened rebound.
The injections imitate a body's own chemical called GLP-1, which controls hunger.
"Long-term administration of GLP-1 levels several times higher than the body's typical production might result in the system to produce less of its endogenous GLP-1, and may also diminish responsiveness to its effects," explained Dr. Adam Collins, a nutrition expert.
"Stopping of this medication results in appetite is uncontrolled, making binge eating far more likely."
A Chronic Condition?
The NHS suggest the jabs for individuals with weight-linked medical conditions, accompanied by recommended diet and exercise modifications.
A number of clinicians argue that, due to the high risk of relapse, the therapy might need to be long-term.
This view is echoed by drug manufacturers, who note that the results "underscore the persistent character of excess weight," similar to managing diseases like hypertension.
User Testimonies
Individuals who have stopped the medication explain a powerful return of cravings.
"It felt as if a switch that goes on and you become ravenous," recalled one woman.
This difficulty is exacerbated if individuals have not adopted lasting lifestyle or habit changes during therapy.
Significant Use
Survey data suggest that a significant number of people in the UK have tried weight-loss jabs in the last 12 months, with desire continuing to grow.
- Use is greater among females compared to males.
- The middle-aged demographic shows the highest usage rates.
- Many obtain the drugs through private prescriptions rather than the NHS.
Finally, researchers emphasize that while the jabs are potent agents for weight loss, they are not a permanent fix and lasting health benefits likely depends on ongoing lifestyle changes.
